Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

ZJ Franklin, LM McShane, Finbarr O'Harte, Nigel Irwin

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P
Original languageEnglish
Pages (from-to)95-101
JournalPeptides
Volume60
DOIs
Publication statusPublished - 18 Aug 2014

Fingerprint Dive into the research topics of 'Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.'. Together they form a unique fingerprint.

  • Cite this